Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012 : a cohort study

Show simple item record

dc.contributor.author Mberi, Mazvita Naome
dc.contributor.author Kuonza, Lazarus R.
dc.contributor.author Dube, Nomathemba Michell
dc.contributor.author Nattey, Cornelius
dc.contributor.author Manda, S.O.M. (Samuel)
dc.contributor.author Summers, Robert
dc.date.accessioned 2015-10-01T08:16:42Z
dc.date.available 2015-10-01T08:16:42Z
dc.date.issued 2015-07-04
dc.description.abstract BACKGROUND : The number of Human Immunodeficiency Virus (HIV) infected people eligible for initiation on antiretroviral Therapy (ART) is increasing. ART programmatic success requires that patients who are taking ART remain on treatment and are followed up regularly. This study investigated factors associated with being lost to follow-up, in a cohort of patients enrolled in a pharmacovigilance study in South Africa. METHODS : This was a retrospective observational cohort study performed at one of the Medunsa National Pharmacovigilance Centre’s (MNPC) ART sentinel surveillance sites. Loss to Follow-up (LTFU) was defined as “a patient who had been followed up at the sentinel site, who had not had contact with the health facility for 180 days or more since their last recorded expected date of return or if there were 180 days or more between the expected date of return and the next clinic visit”. RESULTS : Out of 595 patients, 65.5 % (n = 390) were female and 23.4 % (n = 139) were LTFU. The median time on ART before LTFU was 21.5 months (interquartile range: 12.9 – 34.7 months). The incidence rate of LTFU was 103 per 1000 person-years in the first year on ART and increased to 405 per 1000 person-years in the eighth year of taking ART. Factors associated with becoming LTFU included not having a committed partner (Adjusted Hazard Ratio (aHR): 2.9, 95 % Confidence Interval (CI):1.19-6.97, p = 0.019), being self-employed (aHR: 13.9, 95 % CI:2.81 - 69.06, p = 0.001), baseline CD4 count > 200 cells/ml (aHR: 3.8, 95 % CI: 1.85-7.85, p < 0.001), detectable last known Viral Load (VL) (aHR: 3.6, 95 % CI:1.98 - 6.52, p < 0.001) and a last known World Health Organisation clinical stage three or four (aHR: 2.0, 95 % CI:1.22-3.27, p = 0.006). Patients that previously had an ART adverse event had a lower risk (aHR: 0.6, 95 % CI: 0.38 - 0.99, p = 0.044) of becoming LTFU than those that had not. CONCLUSION : The incidence rate of LTFU increases with additional years on ART. Intensified measures to improve patient retention on ART must be prioritised with increasing patient time on ART and in patients that are at increased risk of becoming lost to follow-up. en_ZA
dc.description.librarian am2015 en_ZA
dc.description.sponsorship The University of Pretoria School of Health systems and Public Health and the South African Field Epidemiology and Laboratory training program. en_ZA
dc.description.uri http://www.biomedcentral.com/bmchealthservres en_ZA
dc.identifier.citation Mberi, MN, Kuonza, LR, Dube, NM, Nattey, C, Manda, S & Summers, R 2015, 'Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012 : a cohort study', BMC Health Services Research, vol. 15, art. no. 258, pp. 1-11. en_ZA
dc.identifier.issn 1472-6963
dc.identifier.other 10.1186/s12913-015-0912-2
dc.identifier.uri http://hdl.handle.net/2263/50129
dc.language.iso en en_ZA
dc.publisher BioMed Central en_ZA
dc.rights © 2015 Mberi et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. en_ZA
dc.subject Surveillance cohort en_ZA
dc.subject Antiretroviral therapy (ART) en_ZA
dc.subject Human immunodeficiency virus (HIV) en_ZA
dc.subject Loss to follow-up (LTFU) en_ZA
dc.title Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012 : a cohort study en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record